Matthew C. Abramowitz

Matthew C. Abramowitz

Auto-generated profile, based on publicly available information

Matthew C. Abramowitz

Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RTRahul D. Tendulkar
Rahul D. Tendulkar
SAShree Agrawal
Shree Agrawal
TGTianming Gao
Tianming Gao
JEJason A. Efstathiou
Jason A. Efstathiou
TPThomas M. Pisansky
Thomas M. Pisansky
ASAndrew J. Stephenson
Andrew J. Stephenson
Purpose: We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era. Methods: Individual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FFBF) and distant metastases (DM) rates were estimated, and predictive nomograms were generated. Results: Overall, 2,460 patients with a median follow-up of 5 years were included; 599 patients (24%) had a Gleason score (GS) ≤ 6, 1,387 (56%) had a GS of 7, 244 (10%) had a GS of 8, and 230 (9%) had a GS of 9 to 10. There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal vesicle invasion (SVI), 1,434 (58%) with positive surgical margins, and 390 (16%) who received ADT (median, 6 months). The median pre-SRT PSA was 0.5 ng/mL (interquartile range, 0.3 to 1.1). The 5-yr FFBF rate was 56% overall, 71% for those with a pre-SRT PSA level of 0.01 to 0.2 ng/mL (n = 441), 63% for those with a PSA of 0.21 to 0.50 ng/mL (n = 822), 54% for those with a PSA of 0.51 to 1.0 ng/mL (n = 533), 43% for those with a PSA of 1.01 to 2.0 ng/mL (n = 341), and 37% for those with a PSA > 2.0 ng/mL (n = 323); P < .001. On multivariable analysis, pre-SRT PSA, GS, EPE, SVI, surgical margins, ADT use, and SRT dose were associated with FFBF. Pre-SRT PSA, GS, SVI, surgical margins, and ADT use were associated with DM, whereas EPE and SRT dose were not. The nomogram concordance indices were 0.68 (FFBF) and 0.74 (DM). Conclusion: Early SRT at low PSA levels after RP is associated with improved FFBF and DM rates. Contemporary nomograms can estimate individual patient outcomes after SRT in the modern era.

29 October 2007 in Cancer
Verified
Journal Article
Closed access
PDF file
MAMatthew C. Abramowitz
Matthew C. Abramowitz
TLTiaynu Li
Tiaynu Li
MBMark K. Buyyounouski
Mark K. Buyyounouski
EREric Ross
Eric Ross
RURobert G. Uzzo
Robert G. Uzzo
EHEric M. Horwitz
Eric M. Horwitz

11 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
Radka StoyanovaRadka Stoyanova
Radka Stoyanova
APAlan Pollack
Alan Pollack
MTMandeep Takhar
Mandeep Takhar
CLCharles Lynne
Charles Lynne
NPNestor Parra
Nestor Parra
AIAdrian Ishkanian
Adrian Ishkanian
Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies

1 May 2018 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
WHWilliam L. Hwang
William L. Hwang
RTRahul D. Tendulkar
Rahul D. Tendulkar
ANAndrzej Niemierko
Andrzej Niemierko
SAShree Agrawal
Shree Agrawal
KSKevin L. Stephans
Kevin L. Stephans
JEJason A. Efstathiou
Jason A. Efstathiou
Importance Prostate cancer with adverse pathological features (ie, pT3 and/or positive margins) after prostatectomy may be managed with adjuvant radiotherapy (ART) or surveillance followed by early-salvage radiotherapy (ESRT) for biochemical recurrence. The optimal timing of postoperative radiotherapy is unclear. Objective To compare the clinical outcomes of postoperative ART and ESRT administered to patients with prostate cancer with adverse pathological features. Design, Setting, and Participants This multi-institutional, propensity score–matched cohort study involved 1566 consecutive patients who underwent postprostatectomy ART or ESRT at 10 US academic medical centers between January 1, 1987, and December 31, 2013. Propensity score 1-to-1 matching was used to account for covariates potentially associated with treatment selection. Data were collected from January 1 to September 30, 2016. Data analysis was conducted from October 1, 2016, to October 21, 2017. Main Outcomes and Measures Freedom from postirradiation biochemical failure, freedom from distant metastases, and overall survival. All outcomes were measured from date of surgery to address lead-time bias. Results Of 1566 patients, 1195 with prostate-specific antigen levels of 0.1 to 0.5 ng/mL received ESRT and 371 patients with prostate-specific antigen levels lower than 0.1 ng/mL received ART. The median age (interquartile range) was 60 (55-65) years. After propensity score matching, the median (interquartile range) follow-up after surgery was similar between the ESRT and ART groups (73.3 [44.9-106.6] months vs 65.8 [40-107] months;P = .22). Adjuvant RT, compared with ESRT, was associated with higher freedom from biochemical failure (12-year actuarial rates: 69% [95% CI, 60%-76%] vs 43% [95% CI, 35%-51%]; effect size, 26%), freedom from distant metastases (95% [95% CI, 90%-97%] vs 85% [95% CI, 76%-90%]; effect size, 10%), and overall survival (91% [95% CI, 84%-95%] vs 79% [95% CI, 69%-86%]; effect size, 12%). Adjuvant RT, lower Gleason score and T stage, nodal irradiation, and postoperative androgen deprivation therapy were favorable prognostic features on multivariate analysis for biochemical failure. Sensitivity analysis demonstrated that the decreased risk of biochemical failure associated with ART remained significant unless more than 56% of patients in the ART group were cured by surgery alone. This threshold is greater than the estimated 12-year freedom from biochemical failure rate of 33% to 52% after radical prostatectomy alone, as determined by a contemporary dynamic nomogram. Conclusions and Relevance Adjuvant RT, compared with ESRT, was associated with reduced biochemical recurrence, distant metastases, and death for high-risk patients, pending prospective validation. These findings suggest that a greater proportion of patients with prostate cancer who have adverse pathological features may benefit from postprostatectomy ART rather than surveillance followed by ESRT.

1 December 2016 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
TPThomas Pisansky
Thomas Pisansky
SAShree Agrawal
Shree Agrawal
DHDaniel A. Hamstra
Daniel A. Hamstra
BKBridget F. Koontz
Bridget F. Koontz
SLStanley L. Liauw
Stanley L. Liauw
RTRahul D. Tendulkar
Rahul D. Tendulkar

1 July 2013 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
AEAhmed Eldefrawy
Ahmed Eldefrawy
DKDevendar Katkoori
Devendar Katkoori
MAMatthew Abramowitz
Matthew Abramowitz
MSMark S. Soloway
Mark S. Soloway
MMMurugesan Manoharan
Murugesan Manoharan